Semaglutide Before and After: Clinical Trial Data
Semaglutide for Weight Loss
14.9%
Mean body weight reduction in the STEP 1 trial after 68 weeks of semaglutide 2.4 mg, compared to 2.4% with placebo.
Wilding et al., New England Journal of Medicine, 2021
Wilding et al., New England Journal of Medicine, 2021
View as imageSocial media is full of dramatic semaglutide before-and-after photos. These images are self-selected, untimed, and uncontrolled. The STEP clinical trial program, a series of large randomized controlled trials, provides the actual data on what semaglutide does to body weight, body composition, and cardiometabolic markers over defined time periods. For a broader overview of the evidence, see the pillar article on semaglutide for weight loss. This article walks through the numbers trial by trial.
Key Takeaways
- STEP 1: semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks in 1,961 adults with obesity, versus 2.4% with placebo[1]
- STEP 3: with intensive behavioral therapy, weight loss reached 16.0% at 68 weeks[2]
- STEP 5: weight loss was sustained at 15.2% through 104 weeks (2 years), demonstrating durability with continued treatment[3]
- STEP 1 extension: participants regained two-thirds of their lost weight within one year of stopping semaglutide[4]
- Semaglutide outperformed liraglutide 3.0 mg: 15.8% vs 6.4% body weight loss at 68 weeks in the STEP 8 head-to-head trial[5]
- SELECT trial: semaglutide 2.4 mg reduced major cardiovascular events by 20% in 17,604 patients with obesity and established cardiovascular disease[6]
STEP 1: The Landmark Trial
The STEP 1 trial (Semaglutide Treatment Effect in People with obesity), published in the New England Journal of Medicine by Wilding et al. (2021), enrolled 1,961 adults with BMI 30 or above (or BMI 27 with at least one weight-related comorbidity) but without diabetes.[1]
Participants were randomized 2:1 to subcutaneous semaglutide 2.4 mg once weekly or placebo, both alongside lifestyle intervention (reduced-calorie diet and physical activity counseling).
The numbers at 68 weeks
- Mean body weight change: -14.9% with semaglutide vs -2.4% with placebo
- Achieved 5% or more weight loss: 86.4% semaglutide vs 31.5% placebo
- Achieved 10% or more weight loss: 69.1% semaglutide vs 12.0% placebo
- Achieved 15% or more weight loss: 50.5% semaglutide vs 4.9% placebo
For a person starting at 105 kg (231 lbs), the average result was losing roughly 15.6 kg (34.4 lbs) over 68 weeks. Half the semaglutide group lost at least 15% of their body weight, a threshold previously achievable mainly through bariatric surgery.
Timeline of weight loss
Weight loss was not linear. The steepest decline occurred during the dose-escalation period and first 20 weeks at full dose. The rate of loss slowed progressively, and body weight approached a plateau between weeks 52 and 68. This pattern reflects the body's metabolic adaptation to reduced caloric intake and the new set point established by GLP-1 receptor activation. More on the dose titration schedule in the article on semaglutide dose escalation.
STEP 2: Patients with Type 2 Diabetes
Weight loss is harder to achieve in people with type 2 diabetes, partly because insulin resistance promotes fat storage and several diabetes medications cause weight gain. STEP 2 tested semaglutide 2.4 mg in 1,210 adults with both obesity and type 2 diabetes.
The result: -9.6% body weight reduction with semaglutide 2.4 mg vs -3.4% with placebo at 68 weeks. The smaller magnitude compared to STEP 1 is consistent across obesity medications; diabetes blunts weight-loss response. Still, nearly 46% of semaglutide-treated patients lost 10% or more of body weight, a result that would have been considered exceptional before GLP-1 agonists.
STEP 3: Adding Intensive Behavioral Therapy
STEP 3 tested whether combining semaglutide with intensive behavioral therapy (a structured 30-session program including meal replacements during the first 8 weeks) would amplify results.[2]
It did, modestly. Mean weight loss reached -16.0% with semaglutide plus intensive behavioral therapy versus -5.7% with placebo plus the same therapy. The added behavioral component contributed roughly 1 percentage point of additional weight loss beyond what semaglutide alone achieved in STEP 1.
STEP 4: What Happens When Treatment Continues vs Stops
STEP 4 used a clever withdrawal design. All 803 participants received semaglutide 2.4 mg for 20 weeks (the dose-escalation phase). Then they were randomized: half continued semaglutide, half switched to placebo for the remaining 48 weeks.[7]
The continued-semaglutide group lost a total of -17.4% body weight by week 68. The switched-to-placebo group regained weight steadily, ending at only -5.0% from their original baseline. The divergence was visible within weeks of discontinuation.
This trial established two things simultaneously: semaglutide's weight loss continues to deepen with ongoing treatment, and stopping the drug leads to rapid regain. For more detail on the regain question, see what happens when you stop taking semaglutide.
STEP 5: Two-Year Durability
The practical question for any weight loss intervention is whether results last. STEP 5 answered this by running for 104 weeks (2 years) with 304 participants.[3]
Mean weight loss at 104 weeks: -15.2% with semaglutide vs -2.6% with placebo. The weight loss achieved by approximately week 60 was maintained through week 104 with continued treatment. There was no late rebound or accelerating tolerance.
This is the longest controlled data for semaglutide 2.4 mg. It shows the drug works as long as you take it, but provides no information on what happens after year two or whether longer-term treatment alters the trajectory.
STEP 8: Head-to-Head Against Liraglutide
Before semaglutide, liraglutide 3.0 mg (Saxenda) was the leading GLP-1 RA for weight management. STEP 8 compared them directly in 338 adults.[5]
At 68 weeks: semaglutide produced -15.8% weight loss versus -6.4% for liraglutide. Semaglutide was administered once weekly; liraglutide required daily injections. On every weight-loss threshold (5%, 10%, 15%, 20%), semaglutide outperformed liraglutide. For context on how these drugs compare, see liraglutide vs semaglutide.
The Weight Regain Problem
Wilding et al. (2022) published the STEP 1 trial extension, following participants for one year after stopping semaglutide at week 68.[4]
The result was sobering. Participants regained roughly two-thirds of their lost weight within 52 weeks of discontinuation. Cardiometabolic improvements (blood pressure, lipids, HbA1c) also reversed partially.
This is not unique to semaglutide. Weight regain after discontinuation of any obesity intervention (pharmacological, surgical, behavioral) is the norm, not the exception. It reflects the biological reality that the hormonal and neural circuits driving body weight regulation reassert themselves when the intervention is removed. The question is not whether semaglutide cures obesity permanently (it does not) but whether continued treatment maintains its benefits (STEP 5 suggests it does).
Beyond Weight: Cardiovascular Outcomes
The SELECT trial, published in the New England Journal of Medicine by Lincoff et al. (2023), enrolled 17,604 patients aged 45 or older with BMI 27 or above and established atherosclerotic cardiovascular disease, but without diabetes.[6]
Semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 20% (hazard ratio 0.80, 95% CI 0.72-0.90) over a mean follow-up of 39.8 months. This made semaglutide the first obesity medication to demonstrate cardiovascular benefit in a dedicated outcomes trial.
The cardiovascular benefit appeared independent of the degree of weight loss, suggesting semaglutide has direct anti-inflammatory or cardioprotective effects beyond its metabolic impact. Kosiborod et al. (2023) showed semaglutide also improved symptoms and exercise function in patients with heart failure with preserved ejection fraction and obesity.[8]
Beyond Weight: Other Organ Systems
The STEP program and related trials documented improvements across multiple systems.[9]
Joint health: Bliddal et al. (2024) showed semaglutide reduced knee pain and improved function in 407 patients with obesity and knee osteoarthritis, with effects that exceeded what would be expected from weight loss alone.[10]
Liver disease: Semaglutide improved markers of liver inflammation and fibrosis in patients with non-alcoholic steatohepatitis (NASH), now renamed MASH.[11]
Quality of life: O'Neil et al. (2022) reported that semaglutide 2.4 mg improved physical functioning, quality of life scores, and reduced total fat mass compared to placebo across the STEP program.[12]
These findings matter because before-and-after data should include more than scale weight. A person who loses 15% of body weight, reduces cardiovascular risk by 20%, and improves joint pain and liver health has experienced a different transformation than the number on the scale alone suggests.
What Body Composition Changes Look Like
The "before and after" that social media does not show is the internal shift in body composition. The concern with rapid weight loss is that muscle mass is lost alongside fat, a problem explored in detail in the article on semaglutide and body composition.
Across the STEP program, approximately 40% of weight lost on semaglutide was lean mass and 60% was fat mass. This ratio is consistent with most weight-loss interventions (dietary, pharmacological, or surgical) and is not unique to semaglutide. The concern escalates at higher rates of weight loss, particularly in older adults who have less lean mass reserve to begin with. Whether exercise or protein supplementation can shift this ratio more favorably during semaglutide treatment is an active research question. For related perspectives, see how much muscle you actually lose on GLP-1 drugs.
What the Before-and-After Photos Leave Out
Clinical trial data reveal what curated social media photos cannot.
Variability is enormous. In STEP 1, while the mean weight loss was 14.9%, individual responses ranged from minimal loss to over 30%. Roughly 14% of semaglutide-treated participants lost less than 5% of body weight. The dramatic transformations posted online represent the high end of the response distribution, not the typical outcome.
Side effects are part of the picture. Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) affected 74.2% of semaglutide participants in STEP 1 versus 47.9% on placebo. Most were mild to moderate and diminished over time, but 7% of semaglutide participants discontinued due to adverse events. The article on GLP-1 side effects covers this in depth.
Weight regain is the rule after stopping. The STEP 1 extension showed two-thirds of lost weight returns within a year of discontinuation.[4] A before-and-after photo taken at peak weight loss does not represent a permanent state unless treatment continues.
The denominator is missing. Photos show the people who respond dramatically. They do not show the non-responders, the people who stopped early due to side effects, or those whose weight loss was modest. Selection bias makes social media before-and-afters a fundamentally misleading data source.
The Bottom Line
The STEP clinical trial program provides rigorous data on semaglutide's weight-loss effects: 14.9% mean body weight reduction at 68 weeks, sustained at 15.2% through 104 weeks with continued treatment, and two-thirds regained within a year of stopping. Beyond weight, semaglutide reduced cardiovascular events by 20% in the SELECT trial and improved joint pain, liver markers, and quality of life. Individual responses vary widely, side effects are common, and the drug works only as long as it is taken. Social media before-and-after photos capture the best-case snapshot but omit the variability, side effects, and regain that clinical trials document.